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The ATM (ataxia telangiectasia mutated) kinase plays an essential role in maintaining genome integrity by coordinating cell cycle arrest,
apoptosis, and DNA damage repair. Phosphorylation of ATM at serine 1981 (ATMpSer1981) by DNA damage activates ATM, which
subsequently phosphorylates H2AX Ser139 (γH2AX), Chk2 Thr68 (Chk2pThr68), and p53 Ser15 (p53pSer15). To determine the role of the ATM
pathway in prostate cancer tumorigenesis, we have analyzed 35 primary prostate cancer specimens for ATMpSer1981 (ATM activation),
Chk2pThr68, γH2AX, and p53pSer15 by immunohistochemistry (IHC) in normal glands, prostatic intraepithelial neoplasias (PINs), and
carcinomas. Increases in the intensities of ATMpSer1981, Chk2pThr68, and γH2AX and in the percentage of cells that are positive for
ATMpSer1981, Chk2pThr68, or γH2AX were observed in PINs (p<0.001) compared to normal prostatic glands and carcinoma. However, this
pattern of immunostaining was not seen for p53pSer15. Thus, ATM and Chk2 are specifically activated in PINs. As PINs are generally regarded as
precursors of prostatic carcinoma, our results suggest that ATM and Chk2 activation at earlier stages of prostate tumorigenesis suppresses tumor
progression, with attenuation of ATM activation leading to cancer progression.
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Prostate cancer is the second leading cause of cancer-related
deaths in males in the developed world [1] and affects one in
nine men over the age of 65 in the United States [2]. Evidence
indicates that the cancer is initiated from prostatic epithelial
cells and progresses into local lesions of PINs before becoming
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doi:10.1016/j.bbamcr.2006.08.026promote prostate tumorigenesis, including the activation of
growth promoting signals (HER-2/neu, ErbB-2, and Akt) [4–8]
and the inactivation of tumor suppressors, Nkx3.1 [9,10], KLF6
[11], p53 [12], p27Kip1 [13–15], and PTEN [16–18].
One of the mechanisms of tumor suppression is the DNA
damage response, which maintains genome stability. Genomic
instability due to the disruption or attenuation of the DNA
damage response is the leading cause of tumorigenesis [19–22].
The ATM (ataxia telangiectasia mutated) kinase plays a central
role in the coordination of the DNA damage response [23,24].
ATM exists as an inactive dimer. The generation of active ATM
monomer is initiated by DNA DSBs (double-stranded breaks)-
induced auto-phosphorylation of Ser1981 of human ATM [25].
ATM activation is facilitated by interaction with the MRE11–
RAD50–NBS1 complex [26]. Activated ATM sets a motion of
downstream events, including phosphorylation of Ser139 of
histone H2AX (γH2AX) [24] and Brca1 to promote DNA
Table 1
Characteristics of patients used in immunohistochemistry analysis
Patient Age of onset Gleason Familial history a
1 61 7 n/a
2 56 6 N
3 57 7 n/a
4 61 7 N
5 57 6 Y
6 50 7 n/a
7 68 7 n/a
8 68 7 Y
9 55 6 n/a
10 61 7 N
11 66 7 Y
12 52 6 Y
13 74 7 n/a
14 62 7 n/a
15 62 7 Y
16 63 7 n/a
17 53 7 N
18 50 7 Y
19 63 7 n/a
20 67 6 n/a
21 66 8 n/a
22 55 7 N
23 58 6 N
24 64 6 n/a
25 65 7 Y
26 66 8 n/a
27 67 6 N
28 69 8 N
29 62 7 Y
30 58 6 n/a
31 51 7 n/a
32 56 7 Y
33 67 7 Y
34 66 7 n/a
35 53 6 N
Mean±SD 60.8±6.2 6.8±0.6
Age of onset (Mean±Standard Deviation, SD), Gleason scores (Mean±
Standard Deviation, SD), and familial history are indicated.
a Familial history is indicated as follows: n/a=Unknown, N=No, Y=Yes.
Patients were asked during the consent process if had knowledge of prostate
cancer among the following family members: brother, father, maternal and
paternal uncles, maternal and paternal grandfathers. Patients who could not
recall this information are listed as “n/a”.
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phosphorylation/activation of Chk2 and phosphorylation/stabi-
lization of p53 [24], leading to cell cycle arrest to repair DNA
damage, or apoptosis if damage is too severe to be repaired.
Thus, inactivation of ATM or components of the ATM pathway,
including MRE11, NBS1, CHK2, and p53 are frequently
observed in human cancers.
One of the functions of tumor suppressors is to sense onco-
genic events in order to stop tumor initiation and progression.
Consequently, this places a selective pressure for the inactivation
of this “tumor surveillance” system in order to promote tumor
progression. p14ARF functions in tumor surveillance [27]. Upon
sensing hyper-proliferative signals, p14ARF suppresses tumor-
igenesis through p53-dependent and -independent pathways
[27]. Interestingly, we have recently shown that ATM con-
tributes to this p14ARF-mediated tumor suppression [28],
indicating a role for ATM in tumor surveillance.
We provide evidence for the first time that ATM is
specifically activated in the process of prostate tumorigenesis.
ATM activation was detected in prostatic glands, PINs, and
prostatic carcinoma. ATM is activated to significantly higher
levels in PINs than in prostatic glands and carcinomas. This
pattern of ATM activation in relation to prostate cancer
progression (initiation-PIN-carcinoma) strongly suggests that
ATM senses prostatic oncogenic events and that attenuation of
ATM activation promotes prostate cancer progression. Consis-
tent with this scenario, we found a similar pattern for Chk2
activation, a substrate of ATM. Comparable findings were also
previously reported in lung and bladder tumors [29,30]. Thus,
our results indicate the involvement of ATM in tumor
surveillance.
2. Materials and methods
2.1. Collection of primary prostate cancer specimens and pathological
examination
Prostate cancer specimens were collected at St. Joseph's Hospital in
Hamilton, Ontario, Canada under the approval from the local Ethics Board and
consent from patients. Cancers were examined and graded according to the
Gleason system by the pathologists (Drs. Sam Salama, Jean-Claude Cutz) at St
Joseph's Hospital [31]. Normal, high grade PINs, and carcinoma areas were
examined in each patient on the same slide. Gleason scores, age of onset of
tumor, and familial history (if available) is presented in Table 1. Tissues were
formalin-fixed, paraffin-embedded, and serially sectioned.
2.2. Immunohistochemistry staining of ATMpSer1981, ChkpThr68,
p53pSer15, and γH2AX
Slides were prepared from paraffin-embedded prostate cancer specimens,
which were deparaffinized in xylene, cleared in a graded ethanol series, and
heat-treated for 20 min in Antigen Unmasking Solution (Vector Laboratories) in
a food steamer. Primary antibodies specific for Ser1981 phosphorylated ATM
(Rockland Inc, 1:100), ATM (Calbiochem, 1:75), Chk2pThr68 (Cell Signaling
Technology, 1:100), p53pSer15 (Cell Signaling Technology, 1:75), p53 (Santa
Cruz Biotechnology, DO-1, 1:100), and γH2AX (Cell Signaling Technology,
1:100) were incubated with the sections overnight at 4 °C. Negative controls
were incubated with a non-specific anti-rabbit IgG. Biotinylated goat anti-rabbit
IgG and Vector ABC reagent (Vector Laboratories) were then sequentially added
according to the manufacturer's instructions. Washes were performed with Tris-
buffered saline with 0.1% Tween-20 (TBST) for Chk2pThr68, p53pSer15, andγH2AX. Phosphate buffered saline (PBS) was used in washes performed for
ATM and Ser1981 phosphorylated ATM. Chromogen reaction was carried out
with diaminobenzidine, and counterstaining was done with hematoxylin.
Competition experiments for immunohistochemistry staining for ATMpSer1981
was tested in 15 specimens by incubating prostate cancer slides with the anti-
pSer1981-ATM antibody in the presence of a competitive peptide, encompass-
ing residues 1974–1988 with Ser1981 phosphorylated (1974-SLAFEEG-pS(1981)-
QSTTISS-1988) overnight, before proceeding to the subsequent procedures as
detailed above. Hematoxylin and eosin (H&E) staining was carried out using a
standard procedure.
2.3. Evaluation of immunohistochemistry staining
We located morphologically normal glands, PINs, and carcinoma on the
same slide from each case to determine the signal intensity of each specific
protein. Approximately 1000 cells were analyzed for each case.
The intensity of staining was double-blind graded on a scale of 1–3
(1=weak staining, 2=moderate staining, and 3=strong staining). We used the
intensity of staining in PINs as the basis for strong staining (see Fig. 1). A
Fig. 1. An anti-Ser1981 phosphorylated ATM (pSer1981-ATM) antibody detects specific signals in PIN. (A) Slides derived from one prostate cancer patient were H&E
stained and immunohistochemically stained with a control (non-specific) IgG or an anti-pSer1981-ATM antibody. Representative images of PINs showing “strong”
staining with anti-pSer1981-ATM, and negative staining with control IgG are presented. (B) Images of a corresponding PIN from the same patient used in panel A that
was H&E stained and immunohistochemically stained with the anti-pSer1981-ATM antibody in the presence or absence of a competitive peptide are shown.
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used to assess the percentage of stained cells in each cell type. The final
composite staining score for immunostaining was based on the intensity of
staining (1, 2, or 3) multiplied by the percentage of immunopositive cells (0–
100).
2.4. Statistical analysis
Statistical analysis was performed using GraphPad Prism 4.0 software for
Windows. The composite staining scores for ATMpSer1981, Chk2pThr68,
γH2AX, and p53pSer15 in normal glands, PINs, and carcinoma were compared
using the Mann–Whitney non-parametric test. A p<0.05 was considered
statistically significant. All p-values are two-tailed.3. Results
3.1. Specific activation of ATM in prostate cancer
tumorigenesis
Cancer results from genome instability and the DNA damage
response is the mechanism that maintains genomic integrity.
ATM kinase plays an essential role in the coordination of the
DNA damage response. The role of ATM in the suppression of
prostate tumorigenesis is unknown. To address this issue, we
have examined ATM activation during the process of prostate
tumorigenesis. Phosphorylation of Ser1981 of ATM disrupts the
ATM dimer, resulting in the generation of active ATMmonomer
[22]. Detection of ATMpSer1981 using a specific antibody
(Rockland Inc) is the most widely used assay for assessing ATM
activation in vivo. Using this system, we could detectATMpSer1981 signals in PIN, since samples incubated with
control Rabbit IgG (Fig 1A) showed no detectable signals.
Furthermore, the ATMpSer1981 signals could be competed-out
by a ATM peptide with Ser1981 phosphorylated [1974-
SLAFEEG-pS(1981)-QSTTISS-1988] (Fig 1B) but not by the
corresponding peptide without Ser1981 phosphorylated [1974-
SLAFEEG-S(1981)-QSTTISS-1988] (data not shown). Con-
sistent with ATM's functions in DNA damage recognition [32],
we were able to demonstrate that ATMpSer1981 signals are
localized exclusively in the nucleus (Fig. 1). Taken together,
these data reveal that the ATMpSer1981 signals detected are
specific for the Ser1981 phosphorylated ATM.
3.2. Higher levels of ATM activation in earlier stages of
prostatic tumorigenesis
The fact that ATM activation was observed in primary
prostate cancer specimens prompted us to determine its
activation in the context of prostate cancer development. It is
believed that high grade PINs are precursors of prostatic
carcinoma [3]. We thus examined ATM activation in morpho-
logically normal prostatic glands, PINs, and carcinomas derived
from the same individual prostate cancer specimens. ATM
activation was detected exclusively in the nuclei of morpho-
logically normal prostatic glands, PINs, and carcinomas (Fig.
2). The levels of ATM activation are relatively lower in normal
prostatic glands and carcinoma when compared to ATM
activation in PINs (Fig. 2). This did not result from differences
in cellularity among these tissues, as a close examination of
Fig. 2. ATM activation in normal prostatic gland, PIN, and carcinoma. Morphologically normal prostatic gland, PIN, and carcinoma from the same patient (or slide)
were H&E stained and immunohistochemically stained for Ser1981 phosphorylated ATM using an anti-pSer1981-ATM antibody. The inset areas are enlarged (right
column).
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of ATM activation in PINs than in both normal prostatic glands
and carcinomas (Fig. 2, far right column). Furthermore, this
analysis was carried out using the same specimen/slide (Fig. 2).
To further confirm that ATM was specifically activated in
PINs, we have analyzed approximately 1000 cells for each cell
type (normal, PIN, and carcinoma) in tissues from individual
patients. In all 35 primary prostate cancer specimens, we could
identify morphologically normal prostatic glands, PINs, and
carcinomas (data not shown). Following the intra-patient
comparison (using normal glands, PINs, and carcinomas withinTable 2
Evaluation of ATMpSer1981, Chk2pThr68, γH2AX, and p53pSer15 immunostainin
Composite staining score a
ATMpSer1981 Chk2pThr68
Median Mean±SD Median
Cell Type Normal 30.0 38.6±20.3 40.0
PIN b 180.0 c 177.7±56.3 160.0c
Carcinoma 40.0 d 48.9±24.2 60.0 e
a Composite score=Staining Intensity (1, 2, or 3)×Percentage of Immunopositive
b PIN, prostatic intraepithelial neoplasia (high-grade).
c Composite staining score was significantly higher in PIN than normal (p<0.001
d There were no significant differences between normal and carcinoma (p=0.08)
e Composite staining score was significantly higher in carcinoma than normal (p=
f Composite staining score was significantly higher in carcinoma than normal (p=
g There were no significant differences between normal, PIN, and carcinoma (p>the same patients/slides), we have determined the levels of ATM
activation in normal glands, PINs, and carcinomas based on a
global composite scoring system (by multiplying the intensity
of staining with the percentage of immunopositive cells; see
Materials and methods for details). We were able to show
elevated ATM activation in PINs when compared its activation
in carcinomas and normal glands (Table 2). Thus, the
differences in ATMpSer1981 observed among normal prostatic
glands, PINs, and carcinomas did not result from immunohis-
tochemistry procedures that were performed separately. Mann–
Whitney test revealed significant differences (p<0.001) in ATMg in human prostatic tissues
γH2AX p53pSer15g
Mean±SD Median Mean±SD Median Mean±SD
42.9±29.0 40.0 46.0±20.3 30.0 28.9±15.1
163.7±45.1 150.0c 155.4±51.7 20.0 33.1±21.8
65.4±37.7 60.0 f 61.7±30.4 30.0 29.4±18.0
Cells (0–100). Maximum score is 300.
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well as between PIN and carcinoma (Table 2). While ATM
activation seems elevated in carcinoma when compared to
normal glands (mean score of 38.6±20.3 and median of 30 for
normal glands versus a mean score of 48.9±24.2 and median of
40.0 for carcinoma) (Table 2), the difference is not statistically
significant (p=0.08) (Table 2). Additionally, the increases in
ATM activation in PINs is not a result of enhanced ATM
expression in PINs, as normal prostatic glands, PINs, and
carcinoma expressed comparable levels of the ATM protein
(Fig. 3, see the total ATM column). Taken together, the above
data demonstrate specific ATM activation in PINs. As the
Gleason scores for our specimens are clustered between 6 and
8 (Table 1), we could not analyze a correlation between ATM
activation and Gleason scores. Nevertheless, as PINs are
generally regarded as precursors of prostate carcinoma, the
above observations indicate that ATM is specifically activated
in earlier stages of prostate tumorigenesis.
3.3. Activation of Chk2 in earlier stages of prostatic
tumorigenesis
To further investigate ATM activation in PINs, we
examined whether ATM activation leads to phosphorylation
of known ATM substrates. Two key ATM substrates are Chk2
and p53. ATM phosphorylates Chk2 Thr68 and p53 Ser15,
resulting in their activation [24]. We were able to demonstrate
increases in Chk2pThr68 in PINs when compared to normal
prostatic glands (Fig 3), with levels of Chk2pThr68 declining
in carcinoma (Fig. 3). Consistent with the nuclear localization
of Chk2pThr68, Chk2pThr68 was detected in the nucleus
(Fig. 3). Mann–Whitney tests confirmed enhanced Chk2
activation (Chk2pThr68) in PINs (p<0.001) than in normal
prostatic glands and carcinoma (p<0.001) (Table 2). While
Chk2 activation is reduced in carcinomas when compared to
PINs (Table 2), its activation is still elevated in carcinoma
versus normal glands (Table 2, p=0.01) (see Discussion for
details).Fig. 3. Enhanced ATMpSer1981, Chk2pThr68, and γH2AX in PINs. The correspondi
or slide were stained immunohistochemically with a control IgG (rabbit) and the indSurprisingly, in all 35 patients examined, there were no
statistically significant differences in p53pSer15 among normal
prostatic glands, PINs, and carcinoma (Fig. 4, Table 2, p>0.05).
p53 is frequently mutated in human cancers and mutant p53 is
commonly more stable than wild type p53. It is thus possible
that the specific conformation of mutant p53 may prevent its
Ser15 from being phosphorylated by ATM. To examine such a
possibility, we have determined p53 protein levels in the
corresponding patients by IHC. No differences in p53 protein
expression were observed among morphologically normal
prostatic glands, PINs, and carcinomas (p>0.05) (Fig. 4).
This pattern is consistent with that of p53pSer15 observed in
those tissues (Fig. 4). These observations thus suggest that
inability to detect changes in p53pSer15 in prostate cancer
development may not be caused by mutations in p53 protein.
Taken together, the above results indicate that ATM may not
phosphorylate p53 Ser15 in prostate tumorigenesis (see
Discussion for details).
As the pattern of Chk2pThr68 closely follows that of
ATMpSer1981 and the coexistence of ATMpSer1981 and
Chk2pThr68 in the same tissues (Fig 3), Chk2 may be a bone
fide ATM target and may play an important role in ATM-
mediated tumor surveillance in prostate tumorigenesis. This
agrees with the concept that the progression from PIN to
carcinoma results from attenuation of ATM activation.
3.4. Specific increases in γH2AX in PINs
We have further determined the possible mechanisms
regulating ATM activation in PINs. Primary ATM-activating
signals are DSBs. The localization of γH2AX to DSBs is
generally believed to be a very early event in the recruitment of
other components of DNA repair machinery onto DNA
damage-induced foci [24], and thus formation of γH2AX is
widely used as an indicator of DNA damage. Accordingly, we
examined the existence of γH2AX in normal prostatic glands,
PINs, and carcinomas. In comparison to normal prostatic glands
and carcinoma, γH2AX was increased in PINs, which localizesng regions in normal prostatic glands, PINs, and carcinoma from the same patient
icated specific antibodies.
Fig. 4. p53 and p53pSer15 staining in normal prostatic gland, PIN, and carcinoma. Corresponding normal prostatic glands, PINs, and carcinoma from the same patient
were stained by immunohistochemistry for p53 and p53pSer15. No significant differences in immunostaining were found for both events (p>0.05).
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significant increase in the levels of γH2AX staining in PINs
compared to normal (p<0.001) and carcinoma (p<0.001)
tissues (Table 2). Although the levels of γH2AX staining are
significantly lower in carcinomas than in PINs, the carcinoma-
associated γH2AX staining is elevated when compared to
normal glands (Table 2, p=0.03). Taken together, the above
observations not only support the possibility that the presence of
DNA damage in the evolution of prostate cancer activates ATM,
but is also consistent with the concept of specific ATM
activation in PINs, as ATM phosphorylates H2AX Ser139 to
produce γH2AX.
4. Discussion
While the DNA damage response plays a major role in tumor
suppression, how this response actively participates in the
suppression of prostate tumorigenesis remains elusive. We
provide evidence that ATM is activated in earlier stages of
prostate tumorigenesis, with activation levels of ATM decreas-
ing as PINs progress into carcinoma. This pattern of ATM
activation reveals that earlier oncogenic events result in ATM
activation, which is attenuated by events occurring in the later
stages of prostate tumorigenesis. It is thus tempting to speculate
that the activation of ATM at the earlier stages of prostate
tumorigenesis prevents tumor progression and its desensitiza-
tion to oncogenic signals promotes tumor development. This
would suggest an intriguing possibility that ATM plays a role in
tumor surveillance, which is supported by our earlier study
showing that ATM contributes to p14ARF-mediated tumor
surveillance [28]. As ATM sits very upstream in the
coordination of the DNA damage response pathway, employing
ATM in the surveillance of oncogenic abnormalities may be a
very effective method of tumor suppression.
Our observed ATM activation in morphologically normal
prostatic glands of prostate cancer tissues may not contradict
with our conclusion involving ATM in prostatic tumor
surveillance. These glands may harbor very early oncogenicevents, as these coexist with PINs and prostatic carcinomas. The
fact that ATM is activated at lower levels in these morpholog-
ically normal glands than in PINs may actually support this
possibility, as one would envisage that ATM activation
increases once oncogenic insults become severe.
The concept of ATM involvement in tumor surveillance is
further supported by two recent publications which demon-
strated increases in ATM activation in lung and bladder pre-
cancerous lesions, and decreases in ATM function in their
respective cancers [29,30]. It has been suggested that abnormal
cell cycle progression via over-expression of cyclin E, Cdc25A,
and E2F1 produces “DNA replication stress” that leads to
activation of the DNA damage response, including ATM
activation and phosphorylation of its downstream targets, p53
Ser15 (p53pSer15), γH2AX, and Chk2 [29,30].
Consistent with these reports, we also found the enhanced
Chk2pThr68 and γH2AX in PINs. Chk2pThr68 and γH2AX
reach the highest levels in PINs and then decrease in carcinoma
(Table 2). In comparison to normal glands, the levels of
Chk2pThr68 and γH2AX are still elevated in carcinoma (Table
2). This pattern of Chk2pThr68 and γH2AX is consistent with
their involvement in the surveillance of prostate tumorigenesis
via ATM. However, as ATM activation is not statistically higher
in carcinoma than in normal glands (Table 2), the fact that both
Chk2pThr68 and γH2AX remain elevated in carcinoma over
normal glands (Table 2) may be attributable to (1) the possible
longer half-life of Chk2pThr68 and γH2AX than the half-life of
ATM activation or (2) additional signals in carcinoma other than
those of tumor surveillance in pre-cancerous lesions (PINs)
resulting in Chk2pThr68 and γH2AX. The latter possibility is
supported by the presence of DNA damage-insults in
carcinoma.
While increases of Chk2pThr68 and γH2AX in PINs support
the involvement of ATM in prostate tumor surveillance, this
pattern is not observed for p53 Ser15, a substrate of ATM.
p53pSer15 is not predominantly increased in PINs over normal
prostatic glands and carcinomas (Table 2). This might not result
from a specific anti-p53pSer15 antibody used. We have
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company (Cell Signaling Technology, #9284) and this antibody
has been demonstrated to recognize p53pSer15 in IHC and
other applications [30]. We were also able to detect p53pSer15
in etoposide-treated culture cells and in primary breast cancer
specimens by IHC (data not shown). Due to our relatively small
sample size, we may not be able to exclude the possibility that
ATM also phosphorylates p53pSer15 in prostate cancer
tumorigenesis. However, the fact that we do see statistically
significant differences in Chk2pThr68 in PINs versus normal
prostatic glands and carcinoma in our limited size of primary
prostate cancer specimens may suggest that ATM phosphor-
ylates Chk2 more efficiently than the phosphorylation of p53
Ser15 in prostate cancer tumorigenesis.
The fact that we could detect activation of the ATM in PINs,
and that only a small portion of carcinoma shows activated
ATM suggests that attenuation of ATM activation may take
place during the progression of PIN lesions to carcinoma. Thus,
reduction of ATM-mediated tumor surveillance may be required
for prostate cancer progression. However, as the activation
levels of ATM and its substrate Chk2 in prostate carcinoma are
not lower than those in morphologically normal prostatic
glands, the ATM pathway in carcinoma may not be defective or
inactivated. Instead, the activation of ATM may be desensitized
or attenuated in response to oncogenic signals to a level that is
sufficient to allow for prostate cancer evolution.
Factors leading to ATM activation may include DNA
damage that might be induced though the hypothetical “DNA
replication stress” mediated by oncogenic signals [29,30]
consistent with the presence of γH2AX in PINs. Thus, ATM
may facilitate the production of γH2AX. Additionally, as Bcl-2
amplification commonly occurs in prostate cancer development
[33–36] and has recently been reported to induce genome
instability by the suppression of DNAmismatch repair [37], it is
thus possible that abnormal Bcl-2 signals may also attribute to
ATM activation in prostate tumorigenesis.
Regardless of what may be the primary causes of ATM
activation, the concept of ATM-mediated tumor surveillance in
prostate cancer tumorigenesis is consistent with reports showing
that ATM polymorphisms, as well as mutations/polymorphisms
of ATM substrates Brca1 and Chk2, are risk factors for prostate
cancer [38–44].
ATM may play multiple roles in prostate tumorigenesis.
While we detected ATM activation without statistically
significant changes in the ATM protein during earlier stages
of prostate tumorigenesis, ATM protein has been reported to
increase in advanced prostate tumors with Gleason scores 8–10
[45]. Thus, it has been suggested that increases in ATM protein
may function in maintaining the shortened telomeres observed
in advanced prostate tumors [45].
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